Archives

Mean glycated hemoglobin level at 26 weeks increased with placebo, decreased with dulaglutide among youth with BMI >85th percentile

40 percent of respondents reported that care team had not discussed trials; concerns about side effects, effectiveness limit participation

Disparities according to race, geographic location, socioeconomic status seen for telehealth use among patients initiating cancer treatment

At week 72, reduction in body weight greater with tirzepatide compared with placebo

Fifty-six percent of patients had pathologic complete response after neoadjuvant treatment with pembrolizumab

ctDNA-guided approach to determining the need for adjuvant therapy noninferior to standard management for recurrence-free survival

Risk for incidence of type 1 diabetes increased 25 percent in association with one increment in BMI standard deviation

Fewer renal complications seen with tirzepatide versus insulin glargine in adults with T2D and increased cardiovascular risk

Cancer-related monthly mortality rate higher in April 2020 when health care capacity was most challenged

Addition of ibrutinib to chemoimmunotherapy prolongs progression-free survival in older patients with untreated mantle-cell lymphoma